Caplin Point Laboratories Ltd
Caplin Point Laboratories Ltd (CAPLIPOINT)

Caplin Point Laboratories Ltd (CAPLIPOINT)


Key Stats

Day's Price Range
52-Week Price Range
1 Month Return-6.9 %
3 Month Return2.85 %
1 Year Return-17.57 %

Company Financials

  • Quarterly
  • Annual
Value in ₹ crore

Peer Comparsion

Rank 124
Rank 50
Rank 99
Dividend Yield
Rank 103
Rank 81
Price To Book Ratio
Rank 187
Debt To Asset
Rank 299

Company Information

Promoted by Mr. C. C. Paarthipan Caplin Point Laboratories Limited was incorporated on April 16th 1990. The Company is a fully integrated Pharma Company and is presently into the business of pharmaceuticals like producing developing and marketing wide range of generic formulations and branded products and exporting to overseas market. Its main research and development facilities are located in Tamil Nadu India and has a manufacturing plant in Puducherry India. It has over 4000 products registrations across the globe with over 650 pharmaceutical formulations over 36 therapeutic sections.Caplin markets a wide spectrum of pharmaceutical formulations and therapeutic segments in 23 countries. In addition to LATAM and Africa it is now serving the US European Union and other regulated markets as well. It manufactures products one among which is for injectables approved interalia by EUGMP INVIMA Colombia Anvisa Brazil and US FDA. Besides these it has extended to regulated markets like USA plans for Canada Australia China and Brazil.The company came out with a public issue in Nov.94 and expanded its production capacity by setting up a new unit to manufacture its range of products at Pondicherry. The company has retained its SSI status even after the expansion and thus will be out of the purview of the DPCO. During 199394 Triwin a partnership firm was merged with Caplin Point. The company entered into a technical agreement with American Remedies and Concord Laboratories US for specific products with a 30 buyback arrangement. It also imports biotechnological products to market them in India.The company has established a trading branch in Nairobi Kenya to sell its products in East Africa. It has also established a warehouse in Miami US by entering into a marketing tieup with Lockett Medical Corporation US.During the year 2015 the Company has invested a sum of Rs 89.10 Lakhs in Argus Salud Pharma LLP. Consequently the Companys share in LLP has increased to 99.90 in Argus Salud Pharma LLP.In October 2016 the Company had subdivided the shares from the face value of Rs 10/ to Rs 2/ and upon subdivision the members were issued five equity shares of Rs 2/ each in lieu of one equity share of Rs 10/ each. After subdivision the paid up capital of Rs151100000 was sub divided into 75550000 equity shares of Rs 2/ each.As on 31 March 2018 the Company has three subsidiaries viz Argus Salud Pharma LLP Caplin Point Far East Limited Hongkong and Caplin Point Laboratories Colombia SAS Colombia.During the year 2019 the Company transferred its regulated markets injectable business which interalia includes US FDA approved injectable plant and Department of Science and Industrial Research DSIR recognised R D Units CP4 and CP 5 to Caplin Steriles Limited a Wholly Owned Subsidiary Company for which the approval was granted by the members of the Company by way of Special Resolution through Postal Ballot on December 31 2018.In FY2019 the Company attracted investments in Caplin Steriles Limited from Eight Roads Ventures India Ill LP and FPrime Capital Partners Life Sciences Fund VI LP in the form of Compulsorily Convertible Preference Shares CCPS which shall be converted into equity shares of Caplin Steriles Limited based on the agreed terms.During FY 2019 the Company formed a Joint Venture Hainan Jointown Caplinpoint Pharmaceutical Company Limited in Hainan Province of China which will be focusing on international trade of medicines and establishment of marketing team in India and China for export of composite formulations to customers in China India Europe and Latin America.In FY21 Company acquired four channel partners in Latin America strengthening control on marketing distribution and supply chain. It launched an ecommerce website named QueTenX a part of the 10X healthcare portal transforming credit sales into cash enhancing an analysis of demand and supply patterns and replenishment stocks through technology tools. It deepened capabilities by stocking essential products at warehouses during the COVID19 months. It commissioned a DGCIapproved CRO facility and captive API development kilo lab to facilitate backward integration. It received approvals for nine of 18 ANDAs filed six for Caplin Steriles five products launched the next four to be launched in the near future. It embarked on a pipeline of 15 ANDAs to be filed within 24 months with an addressable market size of USD 1.95 billion. It completed ab scale batches for 17 products for US by Caplins API division and trebled capacity of the manufacturing facility.The Company received four ANDA approvals since January 2021 increasing approved ANDAs to 15 ten under Caplins name and five through partners. It launched eight products in US four products are ready for launch and three are likely to be launched before December 2021. It received large tender orders worth 18 million in two markets and has started RD for API and Oncology formulations in existing and new markets. The registrations for formulations are in progress as such. The design /detailed engineering for Phase 2 of Injectable Plant is complete. Overall Project cost is Rs. 140 Crore and will include 2 Vial lines one Lyophilizer line one Pre filled syringe line and provision to add another Premix bag line.
OrganisationCaplin Point Laboratories Ltd